Radiation, DNA damage and cancer

Molecular Medicine Today

Volumn 5, Issue 4, 1999, Pages 157-164

  Hall, Janet ^a   Angèle, Sandra ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; GENE PRODUCT; PROTEIN P53; RESTRICTION ENDONUCLEASE; STRESS ACTIVATED PROTEIN KINASE;

ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER; CHROMOSOME 11Q; CHROMOSOME 14; CHROMOSOME 7; CHROMOSOME 8Q; CLINICAL FEATURE; DNA DAMAGE; DNA FINGERPRINTING; FOUNDER EFFECT; HUMAN; IONIZING RADIATION; NIJMEGEN BREAKAGE SYNDROME; NONHUMAN; REVIEW; TUMOR SUPPRESSOR GENE;

ATAXIA TELANGIECTASIA; CELL CYCLE PROTEINS; CHROMOSOME BREAKAGE; DNA; DNA DAMAGE; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; RADIATION TOLERANCE; SYNDROME;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0033120813     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01435-5     Document Type: Review

References (61)

1. Doll R. Prevention of cancer. Pointers from Epidemiology. 1967;The Nuffield Provincial Hospitals Trust.
2. Shiloh Y. Ataxia telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu. Rev. Genet. 31:1997;635-662.
3. Lavin M.F. Radiosensitivity and oxidative signalling in ataxia telangiectasia. Radiother. Oncol. 47:1998;113-123.
4. Mossman K.L. Radiation protection of radiosensitive populations. Health Phys. 72:1997;519-523.
5. Scott D.et al. Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: a test for predisposition. Br. J. Cancer. 77:1998;614-620.
6. Swift M.et al. The incidence and gene frequency of ataxia telangiectasia in the United States. Am. J. Hum. Genet. 39:1986;573-583.
7. Woods C.G., Bundey S.E., Taylor A.M.R. Unusual features in the inheritance of ataxia telangiectasia. Hum. Genet. 84:1990;555-562.
8. Taylor A.M.R., Metcalfe J.A., Thick J., Mak Y-F. Leukemia and lymphoma in ataxia telangiectasia. Blood. 87:1996;423-438.
9. Easton D. Cancer risks in A-T heterozygotes. Int. J. Radiat. Biol. 66:1994;S177-182.
10. Swift M., Reitnauer P.J., Morrell D., Chase C.L. Breast and other cancers in families with ataxia telangiectasia. New Engl. J. Med. 316:1987;1289-1294.
11. Swift M., Morrell D., Massey R.B., Chase C.L. Incidence of cancer in 161 families affected by ataxia telangiectasia. New Engl. J. Med. 325:1991;1831-1836.
12. Pippard E.C., Hall A.J., Barker D.J., Bridges B.A. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res. 48:1988;2929-2932.
13. Borresen A.L.et al. Breast cancer and other cancers in Norwegian families with ataxia telangiectasia. Genes Chromosomes Cancer. 2:1990;339-402.
14. Athma P., Rappaport R., Swift M. Molecular genotyping shows that the ataxia telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet. 92:1996;130-134.
15. Stankovic T.et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer. Am. J. Hum. Genet. 62:1998;334-345.
16. Laake K.et al. Loss of heterozygosity at 11q23.1 in breast carcinomas: indication of a gene distal and close to ATM. Genes Chromosomes Cancer. 18:1997;175-180.
17. van der Burgt I., Chrzanowska K.H., Smeets D., Weemaes C. Nijmegen breakage syndrome. J. Med. Genet. 33:1996;153-156.
18. Seemanová E. An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability. Mutat. Res. 238:1990;321-324.
19. Savitsky K.et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 268:1995;1749-1753.
20. Ko L.J., Prives C. p53:puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
21. Banin S.et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1998;1674-1677.
22. Canman C.E.et al. Activation of the ATM kinase by ionising radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
23. Khanna K.K.et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet. 20:1998;398-400.
24. Kastan M.B.et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
25. Watters D.et al. Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms. Oncogene. 14:1997;1911-1921.
26. Lim D-S.et al. ATM binds to β-adaptin in cytoplasmic vesicles. Proc. Natl. Acad. Sci. U. S. A. 95:1998;10146-10151.
27. Rotman G., Shiloh Y. Ataxia-telangiectasia: is ATM a sensor of oxidative damage and stress? BioEssays. 19:1997;911-917.
28. Taylor A.M.R. What has the cloning of the ATM gene told us about ataxia telangiectasia? Int. J. Radiat. Biol. 73:1998;365-371.
29. Jongmans W.et al. Nijmegen breakage syndrome cells fail to induce the p53-mediated DNA damage response following exposure to ionising radiation. Mol. Cell Biol. 17:1997;5016-5022.
30. Sullivan K.E., Veskler E., Lederman H., Lees-Miller S.P. Cell cycle defects and DNA repair in Nijmegen breakage syndrome. Clin. Immunol. Immunopathol. 82:1997;43-48.
31. Matsuura K.et al. Radiation induction of p53 in cells from Nijmegen breakage syndrome is defective but not similar to ataxia telangiectasia. Biochem. Biophys. Res. Commun. 242:1998;602-607.
32. Yamasaki V., Wegner R.D., Kirchgessner C.U. Characterisation of cell cycle checkpoint responses in Nijmegen breakage syndrome cells. Cancer Res. 58:1998;2316-2322.
33. Stumm M., Sperling K., Wegner R-D. Non-complementation of radiation induced chromosome aberrations in ataxia telangiectasia/ataxia telangiectasia variant heterodikaryons. Am. J. Hum. Genet. 60:1997;1246-1251.
34. Varon R.et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell. 93:1998;467-476.
35. Matsuura S.et al. Positional cloning of the gene for Nijmegen breakage syndrome. Nat. Genet. 19:1998;179-181.
36. Featherstone C., Jackson S.P. DNA repair: The Nijmegen breakage syndrome protein. Curr. Biol. 8:1998;622-625.
37. Hofmann K., Bucher P. The FHA domain: a putative nuclear signalling domain found in protein kinases and transcription factors. Trends Biochem. Sci. 20:1995;347-349.
38. Bork P.et al. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 11:1997;68-76.
39. Carney J.P.et al. The hMre11/hrad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell. 93:1998;477-486.
40. Trujillo K.M., Yuan S.S.F., Lee E.Y.H.P., Sung P. Nuclease activities in a complex of human recombination and DNA repair factors Rad50, Mre11 and p95. J. Biol. Chem. 273:1998;21447-21450.
41. Lieber M.R. Pathological and physiological double-strand breaks - roles in cancer, aging, and the immune system. Am. J. Pathol. 153:1998;1323-1332.
42. Sankaranarayanan K., Chakraborty R. Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. I. Background. Radiat. Res. 143:1995;121-143.
43. Goss P.E., Sierra S. Current perspectives in radiation-induced breast cancer. J. Clin. Oncol. 16:1998;338-347.
44. Brock W.A.et al. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1371-1379.
45. West C.et al. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia telangiectasia (A-T) and A-T heterozygotes. Int. J. Radiat. Biol. 6:1995;175-184.
46. Ramsay J., Birrell G., Lavin M. Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients. Radiother. Oncol. 47:1998;125-128.
47. Ramsay J.et al. Radiosensitive melanoma cell line with mutation of the gene for ataxia telangiectasia. Br. J. Cancer. 77:1998;11-14.
48. Vorechovsky I.et al. Clustering of missense mutations in the ataxia telangiectasia gene in sporadic T-cell leukaemia. Nat. Genet. 17:1997;96-99.
49. Stoppa-Lyonnet D.et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 91:1998;3920-3926.
50. Stilgenbauer S.et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat. Med. 3:1997;1155-1159.
51. Vorechovsky I.et al. ATM mutations in cancer families. Cancer Res. 56:1996;4130-4133.
52. Vorechovsky I.et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumours reveals no evidence for mutation. Cancer Res. 56:1996;2726-2732.
53. Ramsay J., Birrell G., Lavin M. Breast cancer and radiotherapy in ataxia telangiectasia heterozygote. Lancet. 347:1996;1627.
54. Fitzgerald M.G.et al. Heterozygous ATM mutations do not contribute to early onset breast cancer. Nat. Genet. 15:1997;307-310.
55. Appleby J.M.et al. Absence of mutations in ATM gene in breast cancer patients with severe responses to radiotherapy. Br. J. Cancer. 76:1997;1546-1549.
56. Bay J-O.et al. No evidence for constitutional ATM mutation in breast/gastric cancer families. Int. J. Oncol. 12:1998;1385-1390.
57. Gilad S.et al. Predominance of null mutations in ataxia-telangiectasia. Hum. Mol. Genet. 5:1996;433-439.
58. Telatar M.et al. Ataxia-telangiectasia: identification and detection of founder-mutations in the ATM gene in ethnic populations. Am. J. Hum. Genet. 62:1998;86-97.
59. Jackson S.P. DNA damage detection by DNA dependent protein kinase and related enzyme. Cancer Surv. 28:1996;261-279.
60. Feunteun J. Breast cancer and genetic instability: the molecules behind the scenes. Mol. Med. Today. 4:1998;263-267.
61. Baumann P., West S.C. Role of the human RAD51 protein in homologous recombination and double-strand break repair. Trends Biochem. Sci. 23:1998;247-251.